Clinigen Group (CLIN) Given Add Rating at Numis Securities
Several other analysts have also issued reports on the stock. Peel Hunt reiterated a buy rating and issued a GBX 1,350 ($18.31) target price on shares of Clinigen Group in a research note on Wednesday. N+1 Singer reiterated a buy rating and issued a GBX 1,225 ($16.61) target price on shares of Clinigen Group in a research note on Wednesday, November 29th. Royal Bank of Canada reiterated an outperform rating and issued a GBX 1,360 ($18.44) target price on shares of Clinigen Group in a research note on Tuesday, November 7th. Finally, Berenberg Bank began coverage on shares of Clinigen Group in a research note on Wednesday, November 1st. They issued a hold rating and a GBX 1,200 ($16.27) target price for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has an average rating of Buy and an average price target of GBX 1,222.17 ($16.57).
Shares of Clinigen Group (CLIN) opened at GBX 1,059 ($14.36) on Wednesday. Clinigen Group has a one year low of GBX 751.50 ($10.19) and a one year high of GBX 1,187 ($16.10). The company has a market cap of $1,300.00 and a price-to-earnings ratio of 35,300.00.
About Clinigen Group
Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company’s principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.